| PWV quartiles |
---|
1st quartile | 2nd quartile | 3rd quartile | 4th quartile |
---|
cf PWV (m/s) | < 9.5 | 9.5–11.1 | 11.2–13.2 | > 13.2 |
# Incident AF cases | 181 | 57 | 93 | 96 |
Person-time (years) | 5169 | 5153 | 5073 | 5041 |
HR (95% CI) |
Model 1† | 1.60 (1.14, 2.24) | Ref | 1.56 (1.12, 2.17) | 1.47 (1.05, 2.06) |
Model 2‡ | 1.49 (1.06, 2.10) | Ref | 1.59 (1.14, 2.10) | 1.56 (1.10, 2.19) |
Model 3δ | 1.51 (1.07, 2.13) | Ref | 1.63 (1.16, 2.28) | 1.68 (1.18, 2.38) |
Model 4ς | 1.48 (1.05, 2.10) | Ref | 1.64 (1.17, 2.30) | 1.53 (1.8, 2.18) |
Model 5* | 1.51 (1.07, 2.13) | Ref | 1.58 (1.12, 2.21) | 1.58 (1.11, 2.25) |
- Abbreviation: baPWV, brachial-ankle pulse wave velocity; cfPWV, carotid-femoral pulse wave velocity, CI; confidence interval; faPWV: femoral-ankle pulse wave velocity; HR, hazard ratio
- † Model 1: Cox regression model adjusted for sex, age, center, race, education level
- ‡ Model 2: Cox regression model adjusted for sex, age, center, race, education level, systolic blood pressure, diastolic blood pressure, alcohol use, cigarettes smoking, history of myocardial infarction, history of heart failure, body mass index, aspirin, statin, hypertension, diabetes mellitus, left ventricular ejection fraction and left atrial volume
- δModel 3: Model 2 further adjusted for heart failure as a time dependent covariate
- ςModel 4: Model 2 further adjusted for NT-pro B-type natriuretic peptide
- *Model 5: Fine and Gray competing risks model adjusted for variables in model 2, with death considered as a competing risk